Synlogic (NASDAQ:SYBX) Stock Price Crosses Above 50-Day Moving Average – Time to Sell?

Synlogic, Inc. (NASDAQ:SYBX)’s stock price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.69 and traded as high as $0.7230. Synlogic shares last traded at $0.7110, with a volume of 70,770 shares trading hands.

Synlogic Trading Down 0.4%

The company has a market capitalization of $8.32 million, a price-to-earnings ratio of -2.73 and a beta of 0.54. The company’s 50 day simple moving average is $0.69 and its 200-day simple moving average is $0.71.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. DRW Securities LLC purchased a new position in Synlogic during the fourth quarter worth approximately $27,000. Citadel Advisors LLC purchased a new stake in shares of Synlogic during the 3rd quarter valued at $49,000. Finally, Renaissance Technologies LLC grew its stake in shares of Synlogic by 116.7% during the 4th quarter. Renaissance Technologies LLC now owns 85,627 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 46,117 shares during the period. 63.40% of the stock is currently owned by institutional investors and hedge funds.

Synlogic Company Profile

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.